Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Gurion, Ronit; Rozovski, Uri; Itchaki, Gilad; Gafter-Gvili, Anat; Leibovitch, Chiya; Raanani, Pia; Ben-Zvi, Haim; Szwarcwort, Moran; Taylor-Abigadol, Mor; Dann, Eldad J; Horesh, Nurit; Inbar, Tsofia; Tzoran, Inna; Lavi, Noa; Fineman, Riva; Ringelstein-Harlev, Shimrit; Horowitz, Netanel A

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies (MoAb), suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors impacting the response. Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott©) assay in blood samples drawn from lymphoma patients 4±2 weeks after the 2nd vaccine dose. The cutoff for a positive response was set at 50AU/ml. Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of.